Last checked 1 October 2026. General information, not legal or regulatory advice. bioaccess® is not affiliated with, endorsed by, or sponsored by MCRA. Public facts change; verify current terms with qualified advisers.
MCRA is a boutique FDA regulatory advisor for the neuro-musculoskeletal industry — regulatory strategy, gap analysis, IDE and Q-Sub meetings, 510(k), De Novo, and PMA support, with an integrated clinical, reimbursement, and quality arm. bioaccess® is a first-in-human CRO that plans FDA strategy and runs early-feasibility studies across 19 Latin American and Caribbean countries. If your bottleneck is FDA regulatory strategy for an orthopedic or neuro device, MCRA is the specialist. If your bottleneck is executing a first-in-human study, that is bioaccess®. Many sponsors use both, in sequence.
| Metric | bioaccess® | MCRA |
|---|---|---|
| First-in-human clinical-trial operator — FDA strategy plus hands-on study execution across LATAM and the Caribbean | FDA regulatory advisory boutique for the neuro-musculoskeletal industry — regulatory strategy, gap analysis, agency interaction | |
| FDA strategy from Miami — Pre-Sub and EFS-IDE planning anchored to first-in-human execution, not standalone regulatory consulting | Specialist advisory: IDE, De Novo, 510(k), PMA, FDA meeting strategy, pre-clinical and clinical test plans; MCRA publicly cites a track record of nine approved musculoskeletal-device PMAs in the US | |
| FIH-12™ operating model — protocol to first patient in as fast as 4–8 months; 50+ pre-qualified sites across 19 Latin American and Caribbean countries | Integrated clinical research department inside an advisory-led organization | |
| US (FDA strategy from Miami; Amavita Research Miami where a cardiovascular study fits) plus proven execution across 19 Latin American and Caribbean countries | US-focused advisory firm with offices in Washington, DC, Manchester, CT, and New York, NY | |
| Startup-aligned economics — published planning ranges and cost-per-patient transparency | Boutique advisory engagement (project or retainer) | |
| Your risk is execution: you need the first-in-human study run well, fast, and on a startup budget — with the dataset built to survive FDA review | Your risk is regulatory: classification, submission pathway, or FDA meeting strategy for a neuro-musculoskeletal device |
The MCRA column quotes MCRA's public sources listed below. The bioaccess® column comes from bioaccessla.com and reflects our FIH-12™ operating model.
MCRA is the specialist you call when the question is “what does FDA need to see?” — their team has lived inside neuro-musculoskeletal submissions, from IDEs to PMAs, for two decades. That is a different question from “who runs the first-in-human study?”
bioaccess® exists for the second question. We are a first-in-human CRO: FDA strategy from Miami, Pre-Sub and EFS-IDE planning, and hands-on study execution across 19 Latin American and Caribbean countries through our FIH-12™ operating model.
The honest read: for a neuro-musculoskeletal device, these are sequential partners — MCRA shapes the regulatory strategy, bioaccess® executes the early human data. Pick MCRA for the strategy; pick bioaccess® when it's time to run the study.
Only in a narrow slice. MCRA is a capable, reputable CRO. bioaccess® is purpose-built for a single job: first-in-human clinical trials for MedTech, Biopharma and Radiopharma startups, executed across the U.S. and Latin America. If your program is a global pivotal or a post-market study, MCRA is often a better fit. If your program is your first-in-human trial and you need clean, FDA-bridgeable data on a startup budget and timeline, bioaccess® is purpose-built for it.
Clinical data from studies conducted outside the U.S. under ISO 14155 and the Declaration of Helsinki is eligible for FDA submission and review under 21 CFR 812.28 (for devices) and comparable ICH E6 pathways for drugs and biologics. Acceptance is a case-by-case regulatory determination, not a guarantee of clearance or approval — our regulatory team designs the study with the target FDA submission (IDE, 510(k), De Novo, PMA, HDE, IND) as the anchor.
A ~10-patient FIH study through FIH-12™ runs $300K–$500K, with a 12-month protocol-to-LPLV written guarantee and first patient typically 4–8 months after protocol. Per-patient cost is $15K–$35K vs. $40K–$75K in US/EU benchmark ranges. Ethics approval is 4–8 weeks in Latin American jurisdictions vs. 6–12 months in the US/EU.
Yes — sponsors regularly do. A common pattern is to run FIH with bioaccess® in Latin America to generate clean, regulator-ready data fast, then hand off to MCRA (or another CRO suited to that later-phase work) for a multi-region pivotal, registration, or post-market program. Our regulatory strategy is designed to be portable so that data and documentation transfer cleanly to any downstream CRO.
Early feasibility studies are not front-and-center in MCRA's public positioning. Their lane is FDA regulatory strategy and advisory — IDE and Q-Submission meetings, 510(k), De Novo, and PMA support — with an integrated clinical and reimbursement team. If your need is a regulatory strategist for a neuro-musculoskeletal device, that is their home turf; if your need is a CRO to run the first-in-human study across sites, that is what bioaccess® does.
They do different jobs. MCRA advises on the regulatory strategy — what FDA needs to see and how to structure the submission pathway. bioaccess® executes the first-in-human study — protocol, sites, ethics, conduct, and the dataset. Many sponsors sequence the two: strategy first, execution second.
Yes — and that is often the right shape for a neuro-musculoskeletal device. MCRA handles the FDA regulatory strategy while bioaccess® runs the early-feasibility study. Neither is a substitute for the other; they answer different questions.
All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call